Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-27
2005-09-27
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S567000, C514S649000
Reexamination Certificate
active
06949534
ABSTRACT:
The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
REFERENCES:
patent: 4725583 (1988-02-01), Luly et al.
patent: 4826815 (1989-05-01), Luly et al.
patent: 4908360 (1990-03-01), Martin et al.
patent: 5239113 (1993-08-01), Bovy et al.
patent: 5260277 (1993-11-01), McKenzie
patent: 5314902 (1994-05-01), Tjoeng et al.
patent: 5403836 (1995-04-01), Blackburn et al.
patent: 5434188 (1995-07-01), Boschelli et al.
patent: 5693637 (1997-12-01), Klinge et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 43 09 867 (1994-09-01), None
patent: 0 021 234 (1981-01-01), None
patent: 0 357 192 (1990-07-01), None
patent: 0 460 679 (1991-12-01), None
patent: 0 519 748 (1991-12-01), None
patent: 0 565 896 (1993-10-01), None
patent: 0635492 (1995-01-01), None
patent: WO 89/09786 (1989-10-01), None
patent: WO 91/09837 (1991-07-01), None
patent: WO 92/00995 (1992-01-01), None
patent: WO 92/08464 (1992-05-01), None
patent: WO 93/08174 (1993-04-01), None
patent: WO 93/08823 (1993-05-01), None
patent: WO 93/09795 (1993-05-01), None
patent: WO 93/00095 (1993-07-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 94/02445 (1994-02-01), None
patent: WO 94/15958 (1994-05-01), None
patent: WO 94/22825 (1994-10-01), None
patent: WO 94/23714 (1994-10-01), None
patent: WO 95/15973 (1994-12-01), None
patent: WO 95/15963 (1995-06-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/03094 (1997-01-01), None
Zablocki et al., J. Med. Chem. vol. 38(13) (1995) pp. 2378-2394.
Thierry et al., “Synthesis and Activity of NAcSerAspLysPro Analogues on Cellular Interactions between T-Cell and Erythrocytes in Rosette Formation,” Journal of Medical Chemistry, 1990, 33: 2122-2127.
Greenstein et al., “Chemistry of the Amino Acids,” John Wiley & Sons, Inc., vol. 2, 1162-1186.
Kim et al., “Inhibition of125I-Labeled Ristocetin Binding to Micrococcus Luteus Cells by the Peptides Related to Bacterial Cell Wall Mucopeptide Precursors: Quantitative Structure-Activity Relationships,” Journal Medical Chemistry, 1989, 32: 84-93.
Abraham et al., α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway hyperresponsiveness in sheep, J Clin. Invest. 1994, 93(2):776-787.
Bajusz et al., “Design and Synthesis of Peptide Inhibitors of Blood Coagulation”, Folia Haematol. Leipzig, 1982, 109:16-21.
Baldwin et al., “An Efficient Substitute for the α-Aminoadipoyl Moiety of Δ-(L-α-Aminoadipoly)-L-Cysteinyl-D-Valine in the Enzymatic Synthesis of Penicillins”, Tetrahedron, 1987, 43(18): 4217-4220.
Chen et al., Chemical Abstracts, 1991, 115: 159756r.
Chisholm et al., “Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response”, European Journal of Immunology, 1993, 23:682-688.
Elices et al., “Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rheumatoid Arthritis Microvasculature”, The Journal of Clinical Investigation, 1994, 93:405-416.
Ferguson et al., “Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo”, Proceedings of the National Academy of Sciences USA, 1991, 88:8072-8076.
Ferguson et al., “Antigen-Independent Processes in Antigen-Specific Immunity”, The Journal of Immunology, 1993, 150:1172-1182.
Goodman et al., “Synthesis and Conformation of Sequential Polypeptides of L-alanine and beta-Aminobutyric Acid”, Macromolecules, 1976, 9:1-6.
Gruszecki et al., “Diacylamine-perfekte Acylierungsmittel fur die Peptidsynthese”, Liebigs Ann. Chem., 1988, 331-336.
Hemler, “VLA Proteins in the Integrin Family: Structures. Functions. and Their Role on Leukocytes”, Annual Review of Immunology, 1990, 8:365-400.
Jiang et al., “Approaches Toward the Total Synthesis of Astins A, B, And C”, Tetrahedron Letters, 1994, 35:2121-2124.
Komoriya et al., “The Minimal Essential Sequence for a Major Cell Type-specific Adhesion site (CSI) within the Alternatively Spliced . . . ”, Journal of Biological Chemistry, 1991, 266:15075-15079.
Lampi et al., “Comparison of Cell-Permeable Calpain Inhibitors and E64 in Reduction of Cataract in Cultured Rat Lenses”, Toxicology and Applied Pharmacology, 1993, 117: 73-57.
Lobb et al., “The Pathophysiologic Role of α4 Integrins in Vivo”, The Journal of Clinical Investigation, 1994, 94:1722-1728.
Molossi et al., “Blockade of Very Late Antigen-4 Integrin Binding to Fibronectin with Connecting Segment-1 Peptide Reduces Accelerated Coronary Arteriopathy . . . ”, Journal of Clinical_Investigation, 1995, 95:2601-2610.
Morales-Ducret et al., “α4β1, Integrin (VLA-4) Ligands in Arthritis Vascular Cell Adhesion Molecule-1 Expression in Synovium and on . . . ”, The Journal of Immunology, 1992, 149:1424-1431.
Narumiya et al., “Pre-B cells adhere to fibronectin via interactions of integrin α5/αv with RGDS as well as of integrin α4 with two distinct V region sequences at its different . . . ”, Intl. Immun., 1994, 6:139-147.
Nowlin et al., “A Novel Cyclic Pentapeptide Inhibits α4β1 and α5β1 Integrin-mediated Cell Adhesion”, The Journal of Biological Chemistry, 1993, 268:20352-20359.
Sawyer, “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism,”Peptide-Based Drug Design, American Chemical Society, Washington, DC 1995, Chapter 17, pp. 387-410.
Subasinghe et al., “Synthesis of Acyclic and Dehydroaspartic Acid Analogues of Ac-Asp-Glu-OH and Their Inhibition of Rat Brain N-Acetylated alpha-Linked Acidic Dipeptidase (NAALA Dipeptidase)”, Journal of Medicinal Chemistry, 1990, 33:2734-44.
Wayner et al., “Activation-dependent Recognition by Hematopoietic Cells of the LDV Sequence in the V Region of Fibronectin”, The Journal of Cell Biology, 1992, 116:489-497.
Yednock et al., “Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin”, Nature, 1992, 356:63-66.
Goodman et al, The pharmacological basis of therapeutics. 6thed, New York, Macmillan Publishing Inc., 1980, 1738-1740.
Adams Steven P.
Ensinger Carol L.
Zheng Zhongli
Biogen Idec MA Inc.
Celsa Bennett
Steptoe & Johnson LLP
LandOfFree
Cell adhesion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell adhesion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell adhesion inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371479